Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | -2 / 13 |
Beliebteste Broker
News
- 04.10. - 11:00 Uhr
IM Cannabis Announces up to US$1,613,000 Private Placement Offering Led by Management
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and GLIL YAM, Israel , Oct. 4, 2024 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that it intends to undertake a non-brokered private placement offering of up to US$1,613,000 through the sale of approximately 625,000 units (each, an "Unit") at a price per Unit (the "Offering Price") calculated on the basis of the deemed price per common shares in the capital of the Company (each, a "Share") equal to the 10-day volume weighted average price of the Shares on Canadian Securities Exchange (the "Exchange") ending on the trading day preceding October 3, 2024. Each Unit will be comprised of one Share and one Share purchase warrant (each, a "Warrant"). » Mehr auf prnewswire.com
- 02.10. - 12:00 Uhr
IMC Germany Announces Outstanding Preliminary Q3, 2024 Performance with 50% Growth Over Q2
TORONTO and GLIL YAM, Israel , Oct. 2, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that the preliminary sales results in Germany by its German subsidiary, Adjupharm GmbH ("IMC Germany"), for the third quarter of 2024 have significantly exceeded expectations, showing a remarkable 50% increase in revenue compared to the second quarter, where IMC Germany sold about CAD$ 3.5M. This outstanding growth demonstrates IMC Germany's successful execution of its strategic initiatives and strong market demand for its products. » Mehr auf prnewswire.com
- 11.09. - 12:30 Uhr
IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors
TORONTO and GLIL YAM, Israel , Sept. 11, 2024 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. » Mehr auf prnewswire.com
Unternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 10,05 Mio | 10,02% |
Bruttoeinkommen | 575,00k | 75,94% |
Nettoeinkommen | 2,06 Mio | 19,49% |
EBITDA | 1,64 Mio | 271,56% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 4,25 Mio € |
Anzahl Aktien | 2,23 Mio |
52 Wochen-Hoch/Tief | 7,49 € - 1,05 € |
Dividenden | Nein |
Beta | 1,68 |
KGV (PE Ratio) | 0,35 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,90 |
KUV (PS Ratio) | 0,08 |
Unternehmensprofil
IM Cannabis Corp. beschäftigt sich mit der Zucht, dem Anbau und der Lieferung von medizinischen Cannabisprodukten in Israel, Deutschland und Kanada. Das Unternehmen bietet Cannabisblüten und stammspezifische Cannabisextrakte unter der Marke IMC sowie Trockenblüten, Pre-Rolls und gepresstes Haschisch unter den Marken WAGNERS und Highland Grow an. Das Unternehmen beliefert medizinische Patienten und Freizeitkonsumenten. Die IM Cannabis Corp. hat ihren Hauptsitz in Tel Aviv-Yafo, Israel.
Name | IM Cannabis |
CEO | Oren Shuster |
Sitz | Tel Aviv,
Israel |
Website | |
Industrie | Körperpflegeprodukte |
Börsengang | 20.05.2020 |
Mitarbeiter | 95 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | IMCC |
Assets entdecken
Shareholder von IM Cannabis investieren auch in folgende Assets